# OnCo record stampede (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/stampede/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "stampede", "NCT00268476" ;
  schema:name "STAMPEDE"@en ;
  schema:alternateName "STAMPEDE trial"@en, "MRC PR08"@en, "Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy"@en, "STAMPEDE platform"@en ;
  schema:description "STAMPEDE is the longest-running platform trial in oncology, and showed that both docetaxel and abiraterone extend life when started at first diagnosis of metastatic disease."@en ;
  schema:url <https://onco.cc/trials/stampede/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00268476>, <https://doi.org/10.1016/S0140-6736(15)01037-5>, <https://doi.org/10.1056/NEJMoa1702900>, <https://doi.org/10.1016/S0140-6736(18)32486-3>, <https://doi.org/10.1016/S0140-6736(21)02437-5>, <https://doi.org/10.1016/S1470-2045(23)00148-1>, <https://doi.org/10.1016/S0140-6736(21)00100-8>, <https://www.stampedetrial.org>, <https://doi.org/10.1016/S1470-2045(25)00231-1> ;
  onco:status "positive" ;
  onco:phase "platform" ;
  schema:startDate "2005-07-08" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mhspc/>, <https://onco.cc/cancers/prostate-high-risk/> ;
  onco:technologies <https://onco.cc/technologies/androgen-deprivation/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/imrt-igrt/> ;
  onco:drugs <https://onco.cc/drugs/abiraterone/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/enzalutamide/>, <https://onco.cc/drugs/zoledronic-acid/>, <https://onco.cc/drugs/celecoxib/> ;
  onco:companies <https://onco.cc/companies/mrc-ctu/> ;
  onco:institutions <https://onco.cc/institutions/uclh/>, <https://onco.cc/institutions/icr-london/>, <https://onco.cc/institutions/royal-marsden/> ;
  onco:terms <https://onco.cc/terms/master-protocol/>, <https://onco.cc/terms/seamless-adaptive/>, <https://onco.cc/terms/basket-umbrella-platform/>, <https://onco.cc/terms/mcrpc-mhspc/>, <https://onco.cc/terms/interim-analysis/>, <https://onco.cc/terms/prostate-stampede-arms/> ;
  onco:trials <https://onco.cc/trials/patch-transdermal-oestradiol/>, <https://onco.cc/trials/rtog-0521/>, <https://onco.cc/trials/getug-afu-15/> ;
  onco:people <https://onco.cc/people/silke-gillessen/>, <https://onco.cc/people/mahesh-parmar/>, <https://onco.cc/people/nicholas-james/>, <https://onco.cc/people/gerhardt-attard/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-parker-lancet/>, <https://onco.cc/key-papers/paper-langley-lancet/>, <https://onco.cc/key-papers/paper-attard-lancet-oncol/>, <https://onco.cc/key-papers/paper-stampede-lancet-2016/>, <https://onco.cc/key-papers/paper-stampede-plos-med-2022-update/> .